New York State Common Retirement Fund cut its stake in shares of Emergent Biosolutions Inc (NYSE:EBS) by 8.9% in the 4th quarter, HoldingsChannel.com reports. The firm owned 76,818 shares of the biopharmaceutical company’s stock after selling 7,500 shares during the period. New York State Common Retirement Fund’s holdings in Emergent Biosolutions were worth $4,554,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Quantamental Technologies LLC purchased a new position in Emergent Biosolutions in the fourth quarter worth $29,000. Clarus Wealth Advisors raised its position in Emergent Biosolutions by 1,518.0% in the fourth quarter. Clarus Wealth Advisors now owns 1,618 shares of the biopharmaceutical company’s stock worth $96,000 after acquiring an additional 1,518 shares in the last quarter. Smithfield Trust Co. raised its position in Emergent Biosolutions by 272.9% in the fourth quarter. Smithfield Trust Co. now owns 2,446 shares of the biopharmaceutical company’s stock worth $145,000 after acquiring an additional 1,790 shares in the last quarter. Huntington National Bank raised its position in Emergent Biosolutions by 16.6% in the fourth quarter. Huntington National Bank now owns 2,633 shares of the biopharmaceutical company’s stock worth $156,000 after acquiring an additional 374 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its position in Emergent Biosolutions by 37.9% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,083 shares of the biopharmaceutical company’s stock worth $183,000 after acquiring an additional 847 shares in the last quarter. 83.52% of the stock is owned by hedge funds and other institutional investors.

In other news, CEO Daniel Abdun-Nabi sold 14,565 shares of the firm’s stock in a transaction on Monday, March 4th. The stock was sold at an average price of $58.11, for a total value of $846,372.15. Following the completion of the transaction, the chief executive officer now owns 142,617 shares in the company, valued at $8,287,473.87. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, Chairman Fuad El-Hibri sold 10,369 shares of the firm’s stock in a transaction on Tuesday, February 26th. The shares were sold at an average price of $59.65, for a total value of $618,510.85. Following the completion of the transaction, the chairman now owns 1,478,306 shares of the company’s stock, valued at approximately $88,180,952.90. The disclosure for this sale can be found here. In the last 90 days, insiders sold 58,132 shares of company stock valued at $3,411,113. Company insiders own 13.40% of the company’s stock.

Several research firms have issued reports on EBS. Cantor Fitzgerald set a $75.00 price objective on Emergent Biosolutions and gave the stock a “buy” rating in a research report on Thursday, December 13th. Zacks Investment Research upgraded Emergent Biosolutions from a “sell” rating to a “hold” rating in a research report on Thursday, February 28th. ValuEngine cut Emergent Biosolutions from a “buy” rating to a “hold” rating in a research report on Friday, March 1st. Wells Fargo & Co set a $68.00 price objective on Emergent Biosolutions and gave the stock a “hold” rating in a research report on Friday, March 1st. Finally, TheStreet cut Emergent Biosolutions from a “b+” rating to a “c+” rating in a research report on Tuesday, March 12th. Four equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $70.43.

Shares of EBS stock opened at $49.99 on Friday. Emergent Biosolutions Inc has a fifty-two week low of $46.93 and a fifty-two week high of $73.89. The firm has a market capitalization of $2.59 billion, a PE ratio of 21.45, a PEG ratio of 0.87 and a beta of 1.36. The company has a debt-to-equity ratio of 0.78, a current ratio of 3.10 and a quick ratio of 2.07.

Emergent Biosolutions (NYSE:EBS) last announced its quarterly earnings results on Thursday, February 21st. The biopharmaceutical company reported $0.75 earnings per share for the quarter, beating analysts’ consensus estimates of $0.61 by $0.14. Emergent Biosolutions had a return on equity of 12.61% and a net margin of 8.02%. The business had revenue of $270.70 million during the quarter, compared to analysts’ expectations of $269.05 million. During the same quarter last year, the business posted $0.74 earnings per share. The business’s revenue for the quarter was up 39.7% on a year-over-year basis. As a group, sell-side analysts anticipate that Emergent Biosolutions Inc will post 3.27 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This piece was originally posted by Watch List News and is owned by of Watch List News. If you are viewing this piece on another domain, it was stolen and republished in violation of United States & international trademark & copyright law. The correct version of this piece can be accessed at https://www.watchlistnews.com/new-york-state-common-retirement-fund-sells-7500-shares-of-emergent-biosolutions-inc-ebs/2896882.html.

Emergent Biosolutions Company Profile

Emergent BioSolutions Inc focuses on the development, manufacture, and commercialization of medical countermeasures that address public health threats. Its products address public health threats primarily chemical, biological, radiological, nuclear, and explosive-related threats, as well as infectious diseases.

Featured Story: Derivative

Want to see what other hedge funds are holding EBS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Emergent Biosolutions Inc (NYSE:EBS).

Institutional Ownership by Quarter for Emergent Biosolutions (NYSE:EBS)

Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.